查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1917926

体外膜氧合（ECMO）设备市场－2026-2031年预测

Extracorporeal Membrane Oxygenation Machine Market - Forecast from 2026 to 2031
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 150 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

体外膜氧合（ECMO）设备市场预计将从 2025 年的 524,986,000 美元成长到 2031 年的 713,548,000 美元，复合年增长率为 5.25%。

体外膜氧合（ECMO）设备市场在为器官衰竭且常规治疗方法无效的患者提供高级心肺生命支持方面发挥着至关重要的作用。这项先进技术由帮浦、氧合器和插管组成，可暂时取代心臟和/或肺部的功能，从而促进器官恢復。 ECMO 最初是为新生儿护理而开发的，其应用范围已显着扩大，涵盖了患有严重心源性休克、急性呼吸窘迫症候群（ARDS）和体外心肺復苏术（ECPR）的重症成人和儿童患者。该市场的特点是设备安装在三级医疗机构和大学附属医院，需要大量的资金投入、专业的临床技术以及严格的法律规范。

主要市场驱动因素与挑战

市场成长的主要驱动力是全球范围内严重心臟疾病和呼吸系统疾病盛行率的不断上升。急性呼吸窘迫症候群（ARDS）和心源性休克等疾病发生率的增加直接扩大了需要高阶支持的患者群体。由于传统机械通气可能会加重肺损伤，静脉-静脉（VV）体外膜氧合（ECMO）作为一种肺部保护策略，推动了对这类专用系统的需求。同样，心血管疾病负担的加重也推动了静脉-动脉（VA）ECMO的需求，迫使医院系统提升其ECMO能力。

技术进步是第二大成长要素。核心零件的持续创新，特别是高效聚甲基戊烯氧合器和低溶血磁浮离心式帮浦的研发，提高了治疗的安全性和持续时间。这些改进推动了重症监护中心设备的升级和更新。一个关键机会在于日益小型化的携带式氧合（ECMO）系统的研发，这些系统正在拓展其临床应用范围，从ICU内支持扩展到院间转运和院前急救，从而催生了来自急救医疗服务等新兴客户群的需求。

然而，市场面临一个重大限制：治疗总成本高昂。体外主机、一次性迴路以及需要专业人员长期入住加护病房等相关费用高昂，阻碍了ECMO的广泛应用。这一成本障碍抑制了预算敏感型医疗系统的需求，并限制了市场渗透率，尤其是在发展中地区和资源匮乏的环境中。

市场区隔与竞争格局

市场区隔按治疗方法和最终用户划分。静脉-静脉（VV）体外膜氧合（ECMO）领域是一个主要的增长点，这主要得益于全球严重急性呼吸窘迫症候群（ARDS）的流行以及肺部休息疗法的临床应用。医院，尤其是三级医疗机构和教学医院，是主要的最终使用者群体。这些机构拥有必要的多学科团队和基础设施，并且通常被指定为区域ECMO转诊中心，因此需要持续投资于设备和耗材。

竞争格局高度集中，主要由在心肺技术领域拥有长期专业知识的跨国公司主导。主要企业包括美敦力公司（Medtronic plc）、利瓦诺瓦公司（LivaNova）和吉廷格公司（Getinge AB）。竞争的核心在于生物相容性、系统便携性和先进监测功能整合等领域的技术差异化。一次性氧合器和泵浦迴路的可靠性和成本是重要的竞争领域，也是稳定的高收入来源。各公司正透过併购等策略活动来整合产品组合并巩固市场地位。

区域展望

北美保持着市场主导地位，其特点是积极率先采用最尖端科技、拥有高度发达的重症监护基础设施以及有利的报销环境。欧洲紧随其后，这得益于其强大且分散的医疗保健体系和高标准的临床护理。亚太地区，尤其是中国，由于其庞大的患者群体、政府主导的医疗保健现代化以及诸如促进ECMO设备国产化以减少对进口依赖等战略倡议，正迅速成为一个快速扩张的市场。在其他地区，例如中东，政府对专业重症监护中心的投资正在推动市场成长，但公立和私立医疗保健体系之间的市场动态存在显着差异。

本报告的主要优势：

  • 深入分析：提供对主要和新兴地区的深入市场洞察，重点关注客户群、政府政策和社会经济因素、消费者偏好、行业垂直领域和其他细分市场。
  • 竞争格局：了解全球主要企业的策略倡议，并了解透过正确的策略进入市场的可能性。
  • 市场驱动因素与未来趋势：探讨影响市场的动态因素和关键趋势及其对未来市场发展的影响。
  • 可操作的建议：利用这些见解，在快速变化的环境中製定策略决策，发展新的商业机会和收入来源。
  • 受众广泛：对Start-Ups、研究机构、顾问公司、中小企业和大型企业都很有用且经济实惠。

本报告的使用范例

产业与市场分析、机会评估、产品需求预测、打入市场策略、地理扩张、资本投资决策、法规结构及影响、新产品开发、竞争情报

报告范围：

  • 2021年至2025年的历史数据和2026年至2031年的预测数据
  • 成长机会、挑战、供应链前景、法规结构与趋势分析
  • 竞争定位、策略和市场占有率分析
  • 按业务板块和地区（包括国家）分類的收入和预测评估
  • 公司概况（策略、产品、财务资讯、关键发展等）

目录

第一章执行摘要

第二章 市场概览

  • 市场概览
  • 市场定义
  • 调查范围
  • 市场区隔

第三章 商业情境

  • 市场驱动因素
  • 市场限制
  • 市场机会
  • 波特五力分析
  • 产业价值链分析
  • 政策与法规
  • 策略建议

第四章 技术展望

第五章 体外膜氧合（ECMO）设备市场：依产品分类

  • 介绍
  • ECMO装置
  • 软体

6. 体外膜氧合（ECMO）设备市场（依组件划分）

  • 介绍
  • 泵浦
  • 氧合设备
  • 套管
  • 配件

第七章 体外膜氧合（ECMO）设备市场：依模式划分

  • 介绍
  • 静脉-静脉型
  • 静脉-动脉型
  • 动静脉型

第八章 体外膜氧合（ECMO）设备市场：依地区划分

  • 介绍
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 西班牙
    • 其他的
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 其他的
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 韩国
    • 印尼
    • 泰国
    • 其他的

第九章 竞争格局与分析

  • 主要企业和策略分析
  • 市占率分析
  • 合併、收购、协议和合作
  • 竞争对手仪錶板

第十章：公司简介

  • Medtronic plc
  • LivaNova
  • Terumo Cardiovascular Systems Corporation
  • Nipro Medical Corporation
  • Microport Scientific Corporation
  • Getinge AB
  • Xenios AG
  • EUROSETS
  • ABIOMED

第十一章附录

  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关人员的主要收益
  • 调查方法
  • 简称列表
简介目录
Product Code: KSI061615272

The extracorporeal membrane oxygenation machine market, with a 5.25% CAGR, is anticipated to reach USD 713.548 million in 2031 from USD 524.986 million in 2025.

The Extracorporeal Membrane Oxygenation (ECMO) machine market is defined by its critical role in providing advanced cardiac and respiratory life support for patients with organ failure refractory to conventional therapies. This sophisticated technology, comprising a circuit with a pump, oxygenator, and cannulas, temporarily assumes the function of the heart and/or lungs, facilitating organ recovery. Initially developed for neonatal care, its application has expanded significantly to include adult and pediatric populations suffering from severe conditions such as refractory cardiogenic shock, Acute Respiratory Distress Syndrome (ARDS), and during extracorporeal cardiopulmonary resuscitation (ECPR). The market is characterized by its placement within tertiary care and academic medical centers, necessitating substantial capital investment, specialized clinical expertise, and operating under stringent regulatory oversight.

Primary Market Drivers and Challenges

Market growth is primarily driven by the increasing global prevalence of severe cardiac and respiratory diseases. The rising incidence of conditions like ARDS and cardiogenic shock directly expands the patient pool requiring advanced support. As conventional mechanical ventilation can exacerbate lung injury, Veno-Venous (VV) ECMO serves as a lung-protective strategy, thereby driving demand for these specialized systems. Similarly, the growing burden of cardiovascular diseases fuels the need for Veno-Arterial (VA) ECMO, compelling hospital systems to enhance their ECMO capabilities.

Technological advancements constitute a second major growth catalyst. Continuous innovation in core components, particularly the development of high-efficiency polymethylpentene oxygenators and less-hemolytic magnetic levitation centrifugal pumps, improves therapy safety and duration. These enhancements stimulate upgrades and replacements within critical care centers. A significant opportunity lies in the ongoing miniaturization and development of portable ECMO systems, which broaden clinical applications from in-ICU support to inter-hospital transport and pre-hospital care, thereby generating demand from new customer segments like emergency medical services.

However, the market faces a significant constraint in the exorbitant total cost of care. The high expense of the ECMO console, single-use disposable circuits, and the requisite prolonged ICU stay with specialized staff limits broader adoption. This cost barrier suppresses demand in budget-sensitive healthcare systems and restricts market penetration, particularly in developing regions and low-resource settings.

Market Segments and Competitive Landscape

The market is segmented by modality and end-user. The Veno-Venous (VV) ECMO segment is a key growth area, driven by the global prevalence of severe ARDS and the clinical adoption of lung-rest strategies. Hospitals, specifically tertiary care and academic medical centers, represent the dominant end-user segment. These institutions possess the necessary multidisciplinary teams and infrastructure, and are often designated as regional ECMO referral centers, mandating continuous investment in both equipment and disposable components.

The competitive environment is consolidated, dominated by multinational corporations that leverage long-standing expertise in cardiopulmonary technology. Key players include Medtronic plc, LivaNova, and Getinge AB. Competition centers on technological differentiation in areas such as biocompatibility, system portability, and the integration of advanced monitoring features. The reliability and cost of disposable oxygenator and pump circuits represent a consistent, high-volume revenue stream and a critical competitive battleground. Strategic activities, including mergers and acquisitions, are employed to consolidate portfolios and enhance market position.

Geographical Outlook

North America maintains market dominance, characterized by aggressive early adoption of cutting-edge technology, a highly developed critical care infrastructure, and a favorable reimbursement landscape. Europe follows with a robust, decentralized healthcare system and high standards of clinical care. The Asia-Pacific region, particularly China, represents a rapidly expanding market driven by immense patient volume, government-led healthcare modernization, and a strategic push toward domestic manufacturing of ECMO devices to reduce import reliance. Other regions, such as the Middle East, show growth driven by governmental investment in specialized critical care centers, though market dynamics vary significantly between public and private healthcare systems.

Key Benefits of this Report:

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data from 2021 to 2025 & forecast data from 2026 to 2031
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information), and Key Developments among others.

Segmentation

  • By Product
  • ECMO Machine
  • Software
  • By Component
  • Pumps
  • Oxygenators
  • Cannul
  • Accessories
  • By Modality Outlook
  • Veno-Venous
  • Veno-Arterials
  • Arterio-Venous
  • By Geography
  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Others
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Thailand
  • Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

  • 2.1. Market Overview
  • 2.2. Market Definition
  • 2.3. Scope of the Study
  • 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Porter's Five Forces Analysis
  • 3.5. Industry Value Chain Analysis
  • 3.6. Policies and Regulations
  • 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. EXTRACORPOREAL MEMBRANE OXYGENATION MACHINE MARKET BY PRODUCT

  • 5.1. Introduction
  • 5.2. ECMO Machine
  • 5.3. Software

6. EXTRACORPOREAL MEMBRANE OXYGENATION MACHINE MARKET BY COMPONENT

  • 6.1. Introduction
  • 6.2. Pumps
  • 6.3. Oxygenators
  • 6.4. Cannul
  • 6.5. Accessories

7. EXTRACORPOREAL MEMBRANE OXYGENATION MACHINE MARKET BY MODALITY OUTLOOK

  • 7.1. Introduction
  • 7.2. Veno-Venous
  • 7.3. Veno-Arterials
  • 7.4. Arterio-Venous

8. EXTRACORPOREAL MEMBRANE OXYGENATION MACHINE MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. USA
    • 8.2.2. Canada
    • 8.2.3. Mexico
  • 8.3. South America
    • 8.3.1. Brazil
    • 8.3.2. Argentina
    • 8.3.3. Others
  • 8.4. Europe
    • 8.4.1. Germany
    • 8.4.2. France
    • 8.4.3. United Kingdom
    • 8.4.4. Spain
    • 8.4.5. Others
  • 8.5. Middle East and Africa
    • 8.5.1. Saudi Arabia
    • 8.5.2. UAE
    • 8.5.3. Others
  • 8.6. Asia Pacific
    • 8.6.1. China
    • 8.6.2. India
    • 8.6.3. Japan
    • 8.6.4. South Korea
    • 8.6.5. Indonesia
    • 8.6.6. Thailand
    • 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. Medtronic plc
  • 10.2. LivaNova
  • 10.3. Terumo Cardiovascular Systems Corporation
  • 10.4. Nipro Medical Corporation
  • 10.5. Microport Scientific Corporation
  • 10.6. Getinge AB
  • 10.7. Xenios AG
  • 10.8. EUROSETS
  • 10.9. ABIOMED

11. APPENDIX

  • 11.1. Currency
  • 11.2. Assumptions
  • 11.3. Base and Forecast Years Timeline
  • 11.4. Key Benefits for the Stakeholders
  • 11.5. Research Methodology
  • 11.6. Abbreviations